Apeloa Products to Enter the US Market
Zhejiang Jutai Pharmaceutical Co., Ltd., a wholly owned subsidiary of Apeloa Pharmaceutical Co., Ltd., received approval from the U.S. Food and Drug Administration (FDA) on the sustained-release tablet of bupropion hydrochloride (XL).
This medicine is aimed at moderate or severe depression and seasonal affective disorder. It has been sold in the United States since 2003. At present, there is no such product in China.
The company’s product was developed in cooperation with a U.S. company and has been approved by the FDA, which means that their products can now be sold in the U.S. market. Next, the company will actively prepare for the launch of the product.